With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|The Role of LIN28B-let-7-PBK Axis on the Growth and Metastasis of Group 3 Medulloblastoma||Emory University / Shubin Shahab, MD/PhD||Young Investigator Grants||2021||Georgia|
|Function and Dependency of NFkB Activity in ZFTA-RELA Fusion Ependymoma||Baylor College of Medicine / Austin Stuckert, MD||Young Investigator Grants||2021||Texas|
|Role of H3.3-G34R mutation in pediatric high-grade glioma||University of Texas M.D. Anderson Cancer Center / Jian Hu, PhD||Innovation Grants||2021||Texas|
|Unraveling metabolic dependencies in childhood supratentorial ependymomas.||Regents of the University of Michigan / Sriram Venneti, MD/PhD||Innovation Grants||2021||Michigan|
|Hematopoietic stem cell function in familial platelet disorder therapy||University of Massachusetts Medical School / Lucio Castilla, PhD||Innovation Grants||2021||Massachusetts|
|Targeting EZHIP as a therapeutic strategy for infantile ependymomas||University of Wisconsin - Madison / Peter Lewis, PhD||Innovation Grants||2021||Wisconsin|
|Novel targeting approach for pediatric B-cell malignancies||Thomas Jefferson University / Christine Eischen, PhD||Innovation Grants||2021||Pennsylvania|
|Targeting CCAAT/enhancer binding proteins CEBPB and CEBPD in neuroblastoma||Columbia University / Darrell Yamashiro, MD/PhD||Innovation Grants||2021||New York|
|In-vivo characterization of MYCN-driven immunosuppression||University of California San Francisco / William Weiss, MD/PhD||Innovation Grants||2021||California|
|Choline Kinase and Alkylating Agent Resistance in Refractory Childhood Leukemias||Boston Children's Hospital / Alejandro Gutierrez, MD||Innovation Grants||2021||Massachusetts|